BRIEF—New Finnish-South Korean pact to develop controlled release oncology products

Finnish drug delivery company DelSiTech and South Korean biotech company C-Tri have entered into a new collaboration to develop long-acting controlled release formulations.

The firms will focus first on C-Tri’s NHM-CT-007, a peptide drug for oncology.

DelSiTech chief executive Lasse Leino said: “This partnership with C-Tri is an exciting opportunity for DelSiTech. It follows an already successful and long-lasting collaboration with C-Tri in which our Silica Matrix technology has been evaluated.”

DelSiTech has a proprietary ‘Silica Matrix’ technology that’s designed to allow for safe, precise and cost-effective controlled release of drugs.

C-Tri CEO Wan-joo Kim said: “Through this agreement, C-Tri and DelSiTech have an opportunity to be global leaders in developing controlled release oncology drugs.”

“We are confident in taking a step towards entering the global oncology market based on progressing NHM-CT-007 clinical trials in Europe and plan to continue the manufacturing process in Europe as well.”